R

RLS Radiopharmacies

Compounds and dispenses FDA-approved radiopharmaceuticals

Pharmacy Technician

Full-TimeUpdated
No salary listed
Entry
Phoenix, AZ, USA
In Person
Medical, Clinical & VeterinaryPharmacy

About the job

Requirements
  • Eligible to work in the United States.
  • A high school diploma or GED/local equivalent is required.
  • Must be able to accommodate shift changes based on business needs.
  • Must be PTCB certified, complete certification within six months of hire, or be currently enrolled in an accredited school of pharmacy.
  • An applicable state pharmacy technician license is required.
  • Must be able to lift 60 pounds.
  • Proof of COVID-19 vaccination is required to meet customer-mandated on-site compliance obligations.
  • A valid driver's license is required.
  • Previous experience handling radiopharmaceuticals is sought.
  • Previous experience processing prescriptions and/or preparing pharmaceuticals is sought.
  • Previous experience in sterile compounding is sought.
  • Must communicate effectively and professionally.
  • Must be able to prioritize job duties.
  • Must accept and adhere to high ethical values in decisions and actions.
Responsibilities
  • Compound and dispense radiopharmaceuticals under the supervision of a pharmacist.
  • Package radiopharmaceuticals for customer delivery.
  • Perform quality control on compounded products.
  • Manage and maintain facility inventory.
  • Perform cleanroom disinfection tasks and stock sterile supplies.
  • Maintain regulatory program documentation using good documentation practices.
  • Process and/or dual-verify prescription entries.
  • Perform leukocyte labeling procedures.
  • Perform other duties as assigned by the pharmacist.

About the company

R

RLS Radiopharmacies

View
Website

RLS Radiopharmacies provides predictive and diagnostic radiopharmaceutical products and services for molecular imaging within a 100-mile radius of its pharmacies, compounding and dispensing FDA-approved radiopharmaceuticals. It relies on Nuclear Pharmacists and Radiation Safety Officers to ensure quality, with real-time tracking and secure sample access, producing about three million doses per year with a 99.99991% accuracy rate in controlled clean rooms. The company differentiates itself by being the only nationwide radiopharmacy network with The Joint Commission Gold Seal of Approval, combining local service with standardized, high-quality processes. Its goal is to double the size of its network by 2023 to expand reach and service offerings.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Lake Zurich, IL

Founded

2020

Get referred to RLS Radiopharmacies

See people who can refer or advise you

Company News

Contract Pharma
Sep 24th, 2024
Telix Acquires RLS

Expands its North American radiopharmacy network.

MarketScreener
Sep 22nd, 2024
Telix Pharmaceuticals Limited agreed to acquire RLS Inc. from Rls Group Ltd for $250 million.

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million on September 23, 2024.

GlobeNewswire
Sep 22nd, 2024
Telix Acquires RLS to Expand Operations

Telix Pharmaceuticals Limited (ASX: TLX) announced the acquisition of RLS (USA) Inc. from RLS Group Ltd. This move expands Telix’s North American manufacturing and distribution capabilities, leveraging RLS’ 31 radiopharmacies and 100,000 sq ft of expansion space. The acquisition supports Telix’s strategy for a vertically integrated supply chain and enhances its radiometal production network, improving supply chain resilience and patient access across the U.S.

Business Wire
Apr 4th, 2024
Rls Radiopharmacies Partners With Eckert & Ziegler To Expand Production Of Gallium-68-Based Radiopharmaceuticals

LAKE MARY, Fla. & BERLIN--(BUSINESS WIRE)--RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler (ISIN DE0005659700, SDAX). Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals. Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a pivotal role in the accurate diagnosis and subsequent treatment planning for patients with neuroendocrine tumors and prostate cancer.“To help meet the ever-increasing demand for precision diagnostics in cancer treatment, we are collaborating with Eckert & Ziegler to place advanced Ga-68 radiolabeling technology into the hands of all our skilled radiopharmacists nationwide," said RLS CEO Stephen Belcher. “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing. By bringing Eckert & Ziegler’s GalliaPharm® generators into our network, we are closing the patient care gap in many parts of the U.S

Business Wire
Apr 4th, 2024
Rls Radiopharmacies Partners With Eckert Ziegler To Expand Production Of Gallium-68-Based Radiopharmaceuticals

LAKE MARY, Fla. & BERLIN--(BUSINESS WIRE)--RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler (ISIN DE0005659700, SDAX). Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals. Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a pivotal role in the accurate diagnosis and subsequent treatment planning for patients with neuroendocrine tumors and prostate cancer.“To help meet the ever-increasing demand for precision diagnostics in cancer treatment, we are collaborating with Eckert & Ziegler to place advanced Ga-68 radiolabeling technology into the hands of all our skilled radiopharmacists nationwide," said RLS CEO Stephen Belcher. “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing. By bringing Eckert & Ziegler’s GalliaPharm® generators into our network, we are closing the patient care gap in many parts of the U.S